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Strongylus vulgaris is the most pathogenic nematode parasite of horses. Its extensive
migration in the mesenteric blood vessels can lead to life-threatening intestinal infarctions.
Recent work has shown that this parasite is still identified among managed horse
populations. A serum enzyme-linked immunosorbent assay (ELISA) has been developed
for the detection of migrating larvae of S. vulgaris. Previous work has documented an
increase in ELISA values following larvicidal treatment with ivermectin and suggested that
the target parasite antigen is primarily produced by the later larval stages. The aim of
this study was to experimentally inoculate cohorts of foals with S. vulgaris, and then
compare ELISA responses to early or later ivermectin treatments. Fifteen foals were held
in confinement and infected orally with ~25 S. vulgaris third-stage larvae on Days 0, 7, 14,
and 21. Foals were weaned on Day 43 and turned out to a pasture not previously grazed
by horses. Foals remained at pasture continuously until the study was terminated on Day
196. On Day 55, foals were randomly allocated to three treatment groups of five each.
Group 1 received ivermectin on Day 56, Group 2 received ivermectin on Day 112, and
Group 3 foals served as untreated controls. Serum and fecal samples were collected at
28-day intervals throughout the study. Serum samples were analyzed with the S. vulgaris-
specific ELISA and fecal samples were processed for fecal egg counting. The ELISA
values of Group 1 foals were significantly lower than Groups 2 or 3 on Days 140–196. Both
treated groups exhibited increased ELISA values following ivermectin treatment. Results
indicate that the target diagnostic antigen is produced throughout the course of arterial
infection with S. vulgaris, but that an early ivermectin treatment can reduce the cumulative
antigen produced over the course of an infection.
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Introduction
Strongylus vulgaris is considered to be the most pathogenic
helminth parasite of horses due to the extensive migration of its
larval stages. The predilection site for migration is the cranial
mesenteric artery (CMA) and its major branches. Upon infec-
tion, exsheathed third-stage larvae penetrate the large intestinal
mucosa, where they molt to the fourth larval stage (L4) within
the first 5 days. The L4s then migrate proximally toward the
CMA, where they arrive about 11–14 days post infection (PI). In
the CMA, fourth-stage larvae (L4) molt to the immature adult
stage (L5) at about 90 days PI, and migration back to the large
intestine begins around Day 120 PI (1). Migrating larvae cause
fibrinous endarteritis with pronounced thrombosis, formation of
aneurysms, and other pathologic alterations of the vessel struc-
tures (2). Thrombo-embolism caused by L4s and immature adults
has been associated with a painful and often fatal colic syndrome,
characterized by ischemia and non-strangulating infarction of
intestinal segments (3–5).
Historically, S. vulgaris was prevalent in virtually all graz-
ing horses (6–8). However, this pattern changed during the
1980s, when a significant decline was attributed to the inten-
sive anthelmintic treatment regimens typically implemented for
horse populations (9, 10). Notwithstanding, subsequent surveys
of managed horses across the world have documented that S.
vulgaris continues to be encountered on a regular basis (11–
13). One recent study found S. vulgaris DNA in fecal samples
from regularly dewormed thoroughbred mares in Central Ken-
tucky (14). Another recent study conducted in Denmark has even
documented a higher occurrence of S. vulgaris on farms using
a widely recommended parasite control strategy in which treat-
ment decisions are based on pre-treatment fecal egg count levels
(15). Further, a recent retrospective case-control study conducted
among referred Danish equine patients documented a significant
association between non-strangulating intestinal infarctions and
serological evidence of S. vulgaris infection (5). Taken together,
these reports emphasize the need for reliable diagnostic assays to
detect S. vulgaris infections in managed horses.
Recently, a serum enzyme-linked immunosorbent assay
(ELISA) was developed and validated to detect migrating
S. vulgaris larvae in the bloodstream of horses (16). The assay
measures host IgG(T) antibodies against a recombinant S. vulgaris
SXP antigen, Strongylus vulgaris serine-X-proline (SvSXP), and
returns a diagnostic sensitivity of 73.3%, a specificity of 81.0%,
and a statistically significant correlation with the numbers of
migrating larvae in the mesenteric arteries (16). This assay has
been further evaluated and characterized in recent studies. One
study performed with naturally infected foals documented the
presence of maternal antibodies during the first weeks of life, and
found that foals became ELISA-positive between 3 and 5months
of age (17). A second study evaluated the effect of ivermectin
treatment in ELISA-positive juvenile horses and illustrated an
initial increase in ELISA values following treatment, followed by
a decline which was complete after 5months (18). In the same
study, an untreated control group had a significant increase of
ELISA values after approximately 5months of natural exposure to
S. vulgaris infection at pasture. Taken together, these two studies
illustrate that a positive ELISA result represents either current or
recent infection with S. vulgaris within the preceding 5months.
Further, it appears that the SvSXP antigen may be produced
primarily by later larval stages because ELISA values increase
markedly about 5months after first exposure to infection.
The purpose of this study was to test the hypothesis that
SvSXP is primarily produced by the immature L5 stages present
in the CMA after about 90 days PI. The hypothesis was tested
by experimentally infecting cohorts of foals with S. vulgaris and
then comparing SvSXP ELISA responses after early (<90 days)
and later (>90 days) larvicidal treatments with ivermectin.
Materials and Methods
This was a controlled, randomized, blinded prospective clinical
study conducted at a single site between July 2, 2014 and January
14, 2015. The study was reviewed and approved by East Tennessee
Clinical Research’s Institutional Animal Care and Use Committee
(Application No. ETCR-13-0136, approved 22MAY14).
Foals
Fifteen nursing mares with foals-at-side were acquired by East
Tennessee Clinical Research in Rockwood, TN, USA. Prior to the
onset of the study, mares and foals were held in confinement,
and offered a commercial equine concentrate (11% protein) in
quantities totaling ~0.5% of the mare’s body weight, divided into
similar portions offered twice daily. Grass hay was offered twice
daily in quantities totaling ~2.0% of themare’s body weight.Water
from a commercial utility was provided ad libitum.
Approximately 1–4weeks prior to initiation of the trial, all
mares and foals received a larvicidal anthelmintic regimen of fen-
bendazole (10mg/kg once daily for five consecutive days; Panacur
Powerpak, Merck Animal Health, Millsboro, DE, USA). Fecal egg
counts were performed to confirm that the treatment worked.
The 15 foals enrolled in the study were of various light saddle
breeds, including Appaloosa, Quarter Horse, Tennessee Walking
Horse, and Thoroughbred, and were born between April 24 and
June, 2014. Nine were females, and six were intact males. All
underwent a physical examination and were found healthy prior
to the onset of the study.
All foals were inoculated orally with ~25 infective third-stage
larvae (L3) of S. vulgaris on Days 0, 7, 14, and 21. This infective
dose has been successfully used in a previous study (19). On Day
43 (August 14, 2014), foals were separated from their dams and
turned out on a pasture not previously grazed by horses, where
they remained for the duration of the study. After turnout, foals
were offered a commercial equine concentrate (11% protein) in
quantities totaling ~0.25% of body weight once daily. Pasture for-
age was the primary source of fiber and energy, but supplemental
grass hay was available ad libitum whenever pasture forage was
inadequate for maintenance. Water was available ad libitum via
automatic, frost-free hydrants.
Foals were ranked according to their arrival date. Each three
consecutively ranked foals comprised a block, and foals were
allocated randomly from each block to the three treatment group.
Foals assigned to Groups 1 and 2 were treated orally with iver-
mectin (200µg/kg; Zimecterin, Merial Ltd., Duluth, GA, USA) on
Days 56 and 112, respectively. Foals assigned to Group 3 served as
untreated controls. Body weights were measured with a certified
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scale, and fecal and serum samples were collected from each
enrolled foal on Day 0 (July 2, 2014) and repeated thereafter at 28-
day intervals until termination of the study on Day 196 (January
14, 2015).
Randomization of horses to study groups and preparation
of individual doses of ivermectin were completed by personnel
who determined no outcome measures for the duration of the
trial. Administration of the anthelmintic was the responsibility
of employees who remained masked to treatment assignments.
Records of treatment assignments were sequestered away from
masked personnel to prevent inadvertent unblinding.
Preparation and Administration of S. vulgaris
Infective Larvae
Feces were collected from two mares known to have patent S.
vulgaris infections. The mares were residents of the parasitology
research herd of the University of Kentucky (20). Individual 20 g
fecal samples were collected fresh and mixed with equal volumes
of vermiculite (Infinity Fertilizers, Inc., Milan, IL, USA) and
moistened with tap water until pliable. Fecal mixtures were then
suspended in cheesecloth over 10mL of tap water in humidity
chambers as described by Henriksen and Korsholm (21). These
chambers were incubated at ~25°C for 14 days and moistened
as necessary. The fecal mixtures were then sedimented for 24 h
in Baermann apparatuses consisting of wine glasses containing
reservoirs in their stems.
After 24 h, the fecalmixtures were removed from the Baermann
apparatus and the entire contents were centrifuged in multiple
50mL tubes at ~200 g for 10min. The pellets in each tube were
then consolidated into a single 15mL tube per sample and stored
at 25°C until examination. For examination and enumeration of
larvae present, each pellet was re-suspended and transferred to
nematode counting chambers (Chalex Corp., Ketchum, ID, USA).
Nematode slides were examined at 100 magnification. Approx-
imate numbers of S. vulgaris third-stage larvae were recorded,
and other observed species and stages were noted as identified
according to published criteria (22). Larvae were transferred to
15mL tubes, filled with tap water, covered with parafilm, and
capped before shipment to the testing facility (East Tennessee
Clinical Research).
On the days of inoculation, larval counts were conducted, and
volumes of inoculumwere prepared to contain ~25 infective L3s of
S. vulgaris.A separate inoculumwas prepared for each foal; larvae
were transported to the animal facility in individual; labeled 15mL
polypropylene tubes. Larvae were administered orally to each foal
using a separate syringe fitted with polyethylene tubing. After oral
administration of the inoculum, the transport tube was rinsed
with ~5mL of tap water, which was aspirated into the original
inoculation syringe, and administered to the recipient foal in an
identical fashion.
Fecal Egg Counts
Fecal egg counts were performed in triplicate for each enrolled
foal at every scheduled time point, using the mini-FLOTAC
egg counting technique with a detection limit of 5 EPG (23).
A saturated glucose-salt solution was used as flotation medium
(specific gravity: 1.26).
SVSXP Serum ELISA
Serum samples were collected from all enrolled horses at reg-
ular, 28-day intervals throughout the study. An indirect ELISA
using recombinant SvSXP protein as antigen was implemented as
described previously, with duplicatemeasurements of each sample
(16). Serum samples were diluted 1:50 and horseradish peroxidase
(HRP)-conjugated goat anti-horse IgG(T) (Bethyl Laboratories,
Inc., Montgomery, TX, USA) was used as a secondary antibody at
a dilution of 1:40,000. The result was reported as the normalized
value, percentage of a positive control (PP), in order to reduce
inter-assay variability (16).
Strongylus vulgaris-Specific PCR
At termination of the study, strongyle eggs were recovered from
fecal samples collected on Day 196. Strongyle eggs were ana-
lyzed for the presence of S. vulgaris DNA using a species-specific
real-time PCR assay described previously (24). All positive reac-
tions were reanalyzed to rule out false amplification. Results
were reported as the cycle of threshold (Ct) for a positive PCR
amplification, and no amplification in case of PCR negative tests.
Coproculture for Presence of Strongylus vulgaris
Larvae
The samples collected on Day 196 were also coprocultured to test
for the presence of patent S. vulgaris infection. The coproculture
procedure was similar to the one described previously for prepa-
ration of infective inocula. Diagnostic coprocultures utilized 10 g
of feces from each sample, and the entire sediment was collected
from each Baermann apparatus after 48 h of sedimentation. Lar-
vae were identified using published morphological criteria (22).
Statistical Analyses
All analyses were carried out using SAS software (version 9.3, SAS
Institute). Mixed linearmodels were constructed for analyzing the
relationship between serum ELISA values and anthelmintic treat-
ments (group) and time point and the interaction term between
the two. The “mixed” procedure was used with repeated measures
and “foal ID” as random effect. “Group,” “gender,” “age,” and “time
point” were kept as class variables, while all other variables were
considered continuous. The influence of all measured parame-
ters and interactions was evaluated using traditional forward and
backward elimination of variables. All variables with p-values
of 0.20 or below were kept in the model. Variables were log-
transformed to achieve normal distribution, where appropriate.
Whenever the variables “time point,” “group,” or the interaction
term “time point by group” were found significant, a “least square
means” analysis was used for a Tukey’s pairwise comparison.
Results were interpreted at the 0.05 significance level.
Results
The SvSXPELISA valuesmeasured over the course of the study are
presented in Figure 1. All individual ELISA values are included as
supplementary material. Statistical differences between treatment
groups were observed fromDay 140 onward, with Group 1 having
significantly lower mean ELISA values (p< 0.05) than the other
two groups. Results of the Tukey’s pairwise comparison of time
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FIGURE 1 | Serum SvSXP ELISA values presented as a percentage of a
positive control over the course of the 196 study days. Blue diamonds:
group 1 (treated with ivermectin on Day 56), red squares: group 2 (treated with
ivermectin on Day 112), and green triangles: group 3 (no treatment control).
Different letters designate statistically significant differences (p<0.05) between
groups at the given time points. Error bars represent 95% confidence intervals.
TABLE 1 | p-Values generated in the Tukey’s pairwise comparison analysis
of the SvSXP ELISA results obtained at different time points within each
treatment group in the study.
Day 28 54 84 112 140 168 196
Group 1: Ivermectin treatment on day 56
28 –
54 1.0000 –
84 0.1527 0.0042 –
112 0.8788 0.1747 0.9999 –
140 0.0841 0.0017 1.0000 0.9990 –
168 0.1721 0.0051 1.0000 1.0000 1.0000 –
196 0.0065 <0.0001 1.0000 0.8713 1.0000 1.0000 –
Group 2: Ivermectin treatment on day 112
28 –
54 1.0000 –
84 0.9999 0.9922 –
112 <0.0001 <0.0001 <0.0001 –
140 <0.0001 <0.0001 <0.0001 <0.0001 –
168 <0.0001 <0.0001 <0.0001 <0.0001 1.0000 –
196 <0.0001 <0.0001 <0.0001 0.0255 0.3337 0.4014 –
Group 3: No treatment
28 –
54 1.0000 –
84 0.9940 0.9816 –
112 <0.0001 <0.0001 0.0027 –
140 <0.0001 <0.0001 <0.0001 <0.0001 –
168 <0.0001 <0.0001 <0.0001 <0.0001 1.0000 –
196 <0.0001 <0.0001 <0.0001 <0.0001 1.0000 0.9959 –
Significant differences are highlighted in bold.
points within each treatment group are presented in Table 1.
Whereas Group 1 had a steady increase of ELISA values over
the course of the study, the two other groups exhibited increases
betweenDays 84 and 140, after which they both reached a plateau.
Strongyle and ascarid egg count data are presented in Figure 2.
The two ivermectin treatments applied in Groups 1 and 2 reduced
strongyle egg counts by 73 and 100%, respectively, by the next
sampling time point 28 days later. For the ascarid egg counts, no
reduction was observed after the Day 56 ivermectin treatment in
Group 1, whereas the Day 112 treatment in Group 2 reduced the
counts by 100%.
The coproculture and PCR results for detecting patent S. vul-
garis infections at trial termination are presented in Table 2.
Discussion
This study generated useful new information about elaboration
of S. vulgaris-specific antibodies in response to ivermectin treat-
ment of an established infection with migrating larvae. The group
treated early in the infection (Day 56) had a markedly different
ELISA response than control horses or the group treated with
ivermectin on Day 112. While this pattern could suggest differ-
ences in SvSXP antigen production by L4 and L5 larval stages,
increased antibody levels in all groups after Day 56 (Figure 1) are
evidence that antigen is undoubtedly produced by the L4 stages.
It is feasible that the more pronounced ELISA responses in Group
2 and 3 foals was attributable to the continuous and cumulative
production of SvSXP over the course of several months. Previous
work has illustrated that this antigen is highly immunogenic (16),
so continuous release is likely to stimulate a more pronounced
antibody response. The abrupt increases observed after Day 84
in Groups 2 and 3 closely resemble the response observed in a
cohort of foals exposed to natural infection with S. vulgaris (17).
Thus, if left untreated, foals exposed to S. vulgaris infection will
undergo a marked seroconversion, which can be interpreted as
highly indicative of an active arterial infection.
It is worth noting that ELISA values increased following both
ivermectin treatments and that this difference was statistically
significant in Group 1 (Table 1). This finding is consistent with
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FIGURE 2 | Fecal egg counts presented as eggs per gram (EPG) of feces
generated over course of the study. Left graph: strongyle fecal egg count,
right graph: ascarid fecal egg count. White columns: group 1 (ivermectin
treatment on Day 56), gray columns: group 2 (ivermectin treatment on Day 112),
and black columns: group 3 (no treatment control). Error bars represent 95%
confidence intervals.
TABLE 2 | Results of diagnostic work performed for presence patent
Strongylus vulgaris infection at Day 196.
PCRa Coprocultureb
Group 1: Ivermectin treatment on day 56
703 – 4
707 – 0
708 – 0
710 – 0
757 41.46 0
Group 2: Ivermectin treatment on day 112
702 – 0
709 30.26 0
730 38.52 0
733 36.62 0
750 34.53 2
Group 3: No treatment
705 – 0
731 37.16 0
732 33.61 0
753 28.30 8
754 34.90 4
A dash (–) indicates no PCR amplification.
aResults of a S. vulgaris-specific polymerase chain reaction assay reported as the mean
cycle of threshold.
bThe number of S. vulgaris third-stage larvae identified in the entire culture.
observations in a study evaluating ivermectin treatment of nat-
urally infected juvenile horses (18), and we have hypothesized
that this increased antibody production is due to dying worms
which exacerbate interactions with the immune system. It has
been shown that arterial stages of S. vulgaris die over an interval of
4 weeks following ivermectin treatment (25, 26). The nematocidal
activity of ivermectin againstmigrating larvae ismediated through
host immunemechanisms, and dead larvae are eventually translo-
cated from the vessel lumen to the subendothelial tunica media
of the arteries (26). Thus, it appears plausible that an increased
production of antibodies to the SvSXP antigen can occur during a
4-week period following ivermectin treatment.
Table 2 suggests that ivermectin treatment was not 100% effi-
cacious against migrating stages of S. vulgaris in the current
study, and that the efficacy was perhaps even less against the
later stages of infection (L5). Ivermectin is reportedly >98%
efficacious against migrating larvae of S. vulgaris (25, 27, 28),
so historical evidence indicates that a few larvae can survive.
However, these studies all evaluated the efficacy against 56-
day-old experimental infections whereas no published studies
appear to have evaluated ivermectin efficacy against S. vulgaris at
~112 days post inoculation. It is worth noting that fecal samples
from several horses tested PCR positive for S. vulgaris 5months
following ivermectin treatment in a recent study (18). The fecal
egg count reduction observed after ivermectin administration in
group 1 was less than desired, but it should be kept in mind
that pre-treatment egg count levels were very low and that eggs
ingested by coprophagy could constitute a plausible source of
error post-treatment in this age group. Therefore, it remains
possible that a portion of S. vulgaris L5 larvae can survive iver-
mectin treatment. However, this should be evaluated in appro-
priate research studies before any conclusions can be drawn.
It is also worth noticing that the coproculture and the PCR
were not always in perfect agreement. In a previous study, we
have reported a kappa value of 0.5405 between the two tests
(29). One possible explanation is that we routinely examine the
entire sediment of larvae for presence of S. vulgaris, and this
increases the diagnostic sensitivity to a level comparable to the
PCR. Eggs of S. vulgaris are unlikely to be evenly distributed
over the fecal matter, so some of the discrepancy between the
two procedures could simply be due to differences between
subsamples.
The survival of some larvae after ivermectin treatment would
explain the steady increase of antibodies observed in Group 1
during the 5months following treatment (Figure 1). Further,
antibody levels of the other ivermectin-treated horses in Group
2 did not differ from the untreated control group (Group 3) at
any of the seven time points. Again, one possible explanation is
that a portion of S. vulgaris larvae survived treatment and contin-
ued their production of SvSXP. Further, we know from a recent
study that ELISA values do not decrease until about 3–4months
following ivermectin treatment (18). In the present study, this
means that a significant reduction was not likely to occur before
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the termination of the study. Further, since the prepatent period
of S. vulgaris is about 6months, the largemajority of larvae should
have left the vascular development site during the final months
of the study. Perhaps, this exodus can explain the decline of
ELISA values observed in Groups 2 and 3 during the last three
time points. In other words, even the untreated control group
experienced a reduction of arterial larvae during this time, so any
treatment-induced effects on ELISA values in Group 2 would not
be markedly different.
In summary, this study provided documentation that the
SvSXP antigen is apparently produced throughout the course of
arterial infection with S. vulgaris. Thus, our hypothesis that the
antigen is only produced by later migrating stages can be rejected.
However, an early treatment interruption will significantly reduce
the concentration of serum SvSXP-specific antibodies in subse-
quent months. Further, this study also suggested that ivermectin
efficacy against migrating S. vulgaris larvae may be <100%, but
this has yet to be evaluated in appropriate studies.
Author Contributions
CRR andMKN developed the study protocol and oversaw all pro-
cedures. JCP supervised and implemented the clinical elements of
the study. JS, HSG, and JLB contributed substantially to acquisi-
tion and interpretation of the data. MKN drafted the manuscript
with contribution from all authors. The manuscript was critically
reviewed and the final version approved by all authors.
Acknowledgments
This study was supported by Merial Ltd. The authors are grateful
to Dr. Hoyt Cheramie for his support throughout the study.
References
1. Duncan JL, Pirie HM. The life-cycle of Strongylus vulgaris in the horse. Res Vet
Sci (1972) 13:374–9.
2. Duncan JL. Strongylus vulgaris infection in the horse. Vet Rec (1974) 95:34–7.
doi:10.1136/vr.95.2.34
3. Enigk K. Die pathogenese der thrombotisch-embolische kolik des pferdes.
Monatsh Tierheilk (1951) 3:65–74.
4. Duncan JL, Pirie HM. The pathogenesis of single experimental infections with
Strongylus vulgaris in foals. Res Vet Sci (1975) 18:82–93.
5. Nielsen MK, Jacobsen S, Olsen S, Bousquet E, Pihl TH. Non-strangulating
intestinal infarction associated with Strongylus vulgaris in referred Danish
equine patients. Equine Vet J (2015). doi:10.1111/evj.12422
6. Bollinger O. Die kolik der pferde und das wurmaneurysma der eingeweideart-
erien. Akad Wiss Munchen Sitzber (1870) 1:539–44.
7. Robertson D. Intestinal parasites of Shetland Ponies in the North of Scotland.
Vet Rec (1939) 51:779–81.
8. Slocombe JOD, McCraw BM. Gastrointestinal nematodes in horses in Ontario.
Can Vet J (1973) 14:101–5.
9. Herd RP. The changing world of worms – the rise of the cyathostomes and the
decline of Strongylus vulgaris. Comp Cont Educ Pract Vet (1990) 12:732–6.
10. Love S,Duncan JL. Could theworms have turned?EquineVet J (1991) 23:152–4.
doi:10.1111/j.2042-3306.1991.tb02745.x
11. Höglund J, Ljungström BL, Nilsson O, Lundquist H, Osterman E, Uggla A.
Occurrence ofGasterophilus intestinalis and some parasitic nematodes of horses
in Sweden. Acta Vet Scand (1997) 38:157–65.
12. Boxell AC, Gibson KT, Hobbs RP, Thompson RCA. Occurrence of gastroin-
testinal parasites in horses in metropolitan Perth, Western Australia. Aust Vet J
(2004) 82:91–5. doi:10.1111/j.1751-0813.2004.tb14653.x
13. Pilo C, Altea A, Pirino S, Nicolussi P, Varcasia A, Genchi M, et al. Strongylus
vulgaris (Looss, 1900) in horses in Italy: is it still a problem?Vet Parasitol (2012)
184:161–7. doi:10.1016/j.vetpar.2011.09.016
14. Lyons ET, Tolliver SC, Kuzmina T, Dzeverin II, Nielsen MK, McDowell K.
Profiles of strongyle EPG values for thoroughbred mares on 15 farms in Ken-
tucky (2012-2013). Vet Parasitol (2014) 205:646–52. doi:10.1016/j.vetpar.2014.
08.001
15. NielsenMK,VidyashankarAN,Olsen SN,Monrad J, Thamsborg SM. Strongylus
vulgaris associated with usage of selective therapy on Danish horse farms – is it
reemerging? Vet Parasitol (2012) 189:260–6. doi:10.1016/j.vetpar.2012.04.039
16. Andersen UV, Howe DK, Dangoudoubiyam S, Toft N, Reinemeyer CR, Lyons
ET, et al. SvSXP: a Strongylus vulgaris antigen with potential for prepatent
diagnosis. Parasit Vectors (2013) 6:84. doi:10.1186/1756-3305-6-84
17. Nielsen MK, Vidyashankar AN, Gravatte HS, Bellaw J, Lyons ET, Andersen
UV. Development of Strongylus vulgaris-specific serum antibodies in natu-
rally infected foals. Vet Parasitol (2014) 200:265–70. doi:10.1016/j.vetpar.2013.
12.024
18. Nielsen MK, Vidyashankar AN, Bellaw J, Gravatte HS, Cao X, Rubinson EF,
et al. Serum Strongylus vulgaris-specific antibody responses to anthelmintic
treatment in naturally infected horses. Parasitol Res (2015) 114:445–51. doi:10.
1007/s00436-014-4201-5
19. Reinemeyer CR, Prado JC, Andersen UV, Nielsen MK, Schricker B, Kennedy T.
Effects of daily pyrantel tartrate on strongylid population dynamics and perfor-
mance parameters of young horses repeatedly infected with cyathostomins and
Strongylus vulgaris. Vet Parasitol (2014) 204:229–37. doi:10.1016/j.vetpar.2014.
05.034
20. Lyons ET, Tolliver SC, Drudge JH, Swerczek TW, Crowe MW. Common
internal parasites found in the stomach, large intestine, and cranial mesenteric
artery of Thoroughbreds in Kentucky at necropsy (1985-1986). Am J Vet Res
(1987) 48:268–73.
21. Henriksen SA, KorsholmH. Amethod for culture and recovery of gastrointesti-
nal strongyle larvae. Nord Vet Med (1983) 35:429–30.
22. Russell AF. The development of helminthiasis in Thoroughbred foals. J Comp
Pathol Ther (1948) 58:107–27. doi:10.1016/S0368-1742(48)80009-3
23. Barda BD, Rinaldi L, Ianniello D, Zepherine H, Salvo F, Sadutshang T, et al.
Mini-FLOTAC, an innovative direct diagnostic technique for intestinal parasitic
infections: experience from the field. PLoS Negl Trop Dis (2014) 7:e2344. doi:10.
1371/journal.pntd.0002344
24. Nielsen MK, Peterson DS, Monrad J, Thamsborg ST, Olsen SN, Kaplan RM.
Detection and semi-quantification of Strongylus vulgaris DNA in equine faeces
by real-time PCR. Int J Parasitol (2008) 38:443–53. doi:10.1016/j.ijpara.2007.07.
014
25. Slocombe JOD, McCraw BM. Evaluation of ivermectin against later fourth-
stage Strongylus vulgaris in ponies at two and five weeks after treatment. Can
J Comp Med (1984) 48:343–8.
26. Slocombe JOD, McCraw BM, Pennock PW, Ducharme N, Baird JD. Strongylus
vulgaris in the tunicamedia of arteries of ponies and treatment with ivermectin.
Can J Vet Res (1987) 51:232–5.
27. Klei TR, Torbert BJ, Chapman MR, Turk MA. Efficacy of ivermectin in
injectable and oral paste formulations against eight-week-old Strongylus vul-
garis larvae in ponies. Am J Vet Res (1984) 45:183–5.
28. Slocombe JO, McCraw BM, Pennock PW, Vasey J. Effectiveness of ivermectin
against later 4th-stage Strongylus vulgaris in ponies. Am J Vet Res (1982)
43:1525–9.
29. Nielsen MK, Olsen SN, Lyons ET, Monrad J, Thamsborg SM. Real-time PCR
evaluation of Strongylus vulgaris in horses on farms in Denmark and central
Kentucky. Vet Parasitol (2012) 190:461–6. doi:10.1016/j.vetpar.2012.07.018
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Nielsen, Scare, Gravatte, Bellaw, Prado and Reinemeyer. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Veterinary Science | www.frontiersin.org July 2015 | Volume 2 | Article 176
